Ultragenyx Pharma (RARE) PT Lowered to $70 at Baird; Multiple Milestones Ahead
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ultragenyx Pharma (RARE) PT Lowered to $70 at JMP Securities
February 21, 2018 4:35 AM ESTJMP Securities lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $80.00) while maintaining a Market Outperform rating.
... MoreUltragenyx Pharma (RARE) PT Lowered to $74 at Stifel
February 21, 2018 3:32 AM ESTStifel lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $74.00 (from $85.00) while maintaining a Buy rating.
... MoreUltragenyx Pharma (RARE) Tops Q4 EPS by 10c
February 20, 2018 4:12 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.89), $0.10 better than the analyst estimate of ($1.99).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More